Overview
Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra
Status:
Enrolling by invitation
Enrolling by invitation
Trial end date:
2022-09-25
2022-09-25
Target enrollment:
0
0
Participant gender:
All
All
Summary
To determine if the use of Xiidra® reduces ocular surface inflammation in preoperative and postoperative cataract patients.Phase:
Phase 4Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Bucci Laser Vision InstituteTreatments:
Lifitegrast
Ophthalmic Solutions
Criteria
Inclusion Criteria:- Positive for MMP-9 bilaterally as assessed by the Inflammadry assay
Exclusion Criteria:
- Negative Inflammadry assay in either eye
- Active diabetic retinopathy, uncontrolled glaucoma, uncontrolled uveitic inflammation
- Ocular surface diseases that might confound the interpretation of the InflammaDry
assay